Condition: Neoplasms · Adenocarcinoma · Carcinoma · Sponsor: Imperial College London
All patients with recurrent colorectal cancer in the pelvis are eligible. The original primary tumour staging scans and resected surgical specimen needs to be available. Patients' recurrence will be staged using our proposed MRI classification. We will be assessing the original primary staging scans and histopathology to learn about risk factors for recurrence. We will record treatment for the recurrence, and patients will be followed up for three years.
This description comes directly from the study's public registry record.
Caroline Martin · +44 (0) 7749 655 817 · c.martin1@imperial.ac.uk
Syvella Ellis · +44 (0) 7732 315 234 · giclinicaltrials@imperial.ac.uk
Always discuss trial participation with your own doctor first.
| Oslo University Hospital | Oslo, Norway | Recruiting |
| St Mark's Hospital | Harrow, London, United Kingdom | Recruiting |
| Churchill Hospital | Oxford, Oxfordshire, United Kingdom | Recruiting |
| Royal Marsden Hospital NHS Foundation Trust | Sutton, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02292641